Director Bruno Lucidi of Atea Pharmaceuticals, Inc. filed a Form 4 on November 19, 2026, disclosing option exercises and related share sales on November 17 and November 19, 2026.
Key Highlights
- First option exercise: On November 17, 2026, Lucidi exercised 21,628 stock options at an exercise price of $1.24 per share, acquiring 21,628 shares of common stock.
- Second option exercise: On November 19, 2026, Lucidi exercised 53,372 stock options at an exercise price of $1.24 per share, acquiring 53,372 shares of common stock.
- Shares sold on November 17: 6,741 shares were disposed of at a weighted average price of $4.0335, with individual sale prices ranging from $4.00 to $4.10.
- Shares sold on November 19: 22,619 shares were disposed of at a weighted average price of $3.9445, with individual sale prices ranging from $3.91 to $3.97.
- Resulting ownership: Following all reported transactions, Lucidi directly beneficially owned 187,990 shares of Atea Pharmaceuticals common stock.
- Purpose stated: According to the filing, "All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes."
Lucidi's Two-Day Option Exercise and Share Disposition Activity
According to the Form 4 filed on NASDAQ:AVIR, director Bruno Lucidi of Atea Pharmaceuticals, Inc., a biopharmaceutical company, conducted a series of transactions across two dates. On November 17, 2026, Lucidi exercised 21,628 fully vested stock options at an exercise price of $1.24 per share, acquiring 21,628 shares of common stock and bringing his direct beneficial ownership to 163,978 shares at that point. He then sold 6,741 shares at a weighted average price of $4.0335, with sales occurring in multiple transactions at per-share prices ranging from $4.00 to $4.10, reducing his direct holdings to 157,237 shares.
On November 19, 2026, Lucidi exercised an additional 53,372 fully vested stock options, again at the $1.24 exercise price, acquiring 53,372 more shares and increasing his direct holdings to 210,609 shares. He then sold 22,619 shares at a weighted average price of $3.9445, with individual sale prices ranging from $3.91 to $3.97 per share, leaving his final reported direct beneficial ownership at 187,990 shares. The filing notes that both options carried a December 8, 2026 expiration date and were fully vested and exercisable at the time of exercise.
The filing was signed by Andrea Corcoran as Attorney-in-Fact for Bruno Lucidi. Lucidi is identified solely as a director of Atea Pharmaceuticals, which is listed on NASDAQ under the ticker AVIR. The filing indicates that after the November 19 transactions, no derivative securities in the form of stock options at the $1.24 exercise price remain beneficially owned by Lucidi.
What Was Disclosed
Director Bruno Lucidi disclosed two option exercises and two sets of share sales at Atea Pharmaceuticals over November 17-19, 2026, with the sales attributed to covering the exercise price and tax planning. His direct beneficial ownership stood at 187,990 shares after all reported transactions.




Please wait processing your request...